$AZTR News

Last published 15h ago

15h agoAZTRAzitra, Inc. Announces Q3 2026 Results and Provides Business UpdatesPR NewswireAzitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative...
16h agoAZTRAzitra, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
2d agoAZTRAzitra, Inc. to Present Research at BIO-Europe® Showing ATR-COSF Reduced Fine Lines and Improved Elasticity in Ex Vivo Human Skin ModelsPR NewswireAzitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative...
2w agoAZTRAzitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK InhibitorsPR NewswireExpanded eligibility significantly broadens potential treatment opportunities for ATR-04 beyond EGFR inhibitor-associated skin rashAdditional protocol modifications expected to facilitate patient recruitment and
2w agoAZTRAzitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human SkinPR NewswireATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin.Ex vivo data in two models of recent cosmetic surgery explants showed visible improvements in fine
4w agoAZTRAzitra, Inc. Announces Reverse Stock SplitPR NewswireCommon Stock Will Begin Trading on a Split-Adjusted Basis on October 26, 2026BRANFORD, Conn., Oct. 16, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing
1mo agoAZTRAzitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee ClearancePR NewswireAzitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies ...
2mo agoAZTRAzitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment ConferencePR NewswireAzitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies ...
2mo agoAZTRAzitra, Inc. Regains Compliance with NYSE American Continued Listing StandardsPR NewswireAzitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies ...
3mo agoAZTRAzitra, Inc. Announces Q2 2026 Results and Provides Business UpdatesPR NewswireBRANFORD, Conn., Aug. 12, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision
4mo agoAZTRAzitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and ElasticityPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology...
4mo agoAZTRAzitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and BeyondPR NewswireAzitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies ...
4mo agoAZTRAzitra, Inc. to Present at 2026 BIO International ConventionPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
5mo agoAZTRAzitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened MeetingPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
5mo agoAZTRAzitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual MeetingPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
6mo agoAZTRAzitra, Inc. Announces Q1 2026 Results and Provides Business UpdatesPR NewswireAzitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies ...
6mo agoAZTRAzitra, Inc. Announces New U.S. Patent Protecting ATR-12 ProgramPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
6mo agoAZTRAzitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis VulgarisPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
7mo agoAZTRAzitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 MillionPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
8mo agoAZTRAzitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public AnnouncementPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
8mo agoAZTRAzitra, Inc. Announces Cancellation of 2026 Special Meeting of StockholdersPR NewswireAzitra, Inc. (NYSE American: AZTR) ("Azitra" or the "Company"), a clinical stage biopharmaceutical company focused on developing innovative therapies ...
8mo agoAZTRAzitra, Inc. Announces Full Year 2025 Results and Provides Business UpdatesPR NewswireAzitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision...
8mo agoAZTRAzitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin RashPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
8mo agoAZTRAzitra, Inc. to Present at BIO Investment & Growth SummitPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
9mo agoAZTRAzitra Announces Adjournment of Special Meeting and Information for Reconvened Special MeetingPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
10mo agoAZTRAzitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare ConferencePR NewswireAzitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision...
11mo agoAZTRAzitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE AmericanPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
11mo agoAZTRAzitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE RulesPR NewswireAzitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision...
1y agoAZTRAzitra, Inc. Announces Q3 2025 Results and Provides Business UpdatesPR NewswireGeneral and Administrative (G&A) expenses: G&A expenses for the quarter ended September 30, 2025, were $1.6 million compared to $1.9 million for the...
1y agoAZTRAzitra, Inc. Addresses False Report Regarding Sale of SecuritiesPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
1y agoAZTRAzitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis VulgarisPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
1y agoAZTRAzitra to Participate in Dermatologic Rare Disease Panel at Maxim Growth SummitPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
1y agoAZTRAzitra Receives Notice of Non-Compliance from NYSE AmericanPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
1y agoAZTRAzitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment ConferencePR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
1y agoAZTRAzitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated RashPR NewswireAzitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision...
1y agoAZTRAzitra, Inc. Announces Q2 2025 Results and Provides Business UpdatesPR NewswireAzitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision...
1y agoAZTRAzitra, Inc. Announces Reverse Stock SplitPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
1y agoAZTRAzitra Reports Promising Safety Data from Phase 1b Trial in Netherton SyndromePR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
1y agoAZTRAzitra, Inc. Announces Presentation at the 2025 BIO International ConventionPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
1y agoAZTRAzitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated RashPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
1y agoAZTRAzitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated RashPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
1y agoAZTRAzitra, Inc. Announces Q1 2025 Results and Provides Business UpdatesPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
1y agoAZTRAzitra, Inc. to Present ATR-04 Program Update at ASCO 2025PR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
1y agoAZTRAzitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical PipelinePR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
1y agoAZTRAzitra to Present at Microbiome Times Partnering ForumPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
1y agoAZTRAzitra, Inc. Announces Full Year 2024 Financial Results and Provides Business UpdatesPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
1y agoAZTRAzitra Announces Pricing of $930.0 Thousand Registered Direct Offering of Common StockPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
1y agoAZTRAzitra, Inc. to Present at the BIO CEO & Investor ConferencePR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
1y agoAZTRAzitra, Inc. to Present at The Microcap ConferencePR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
1y agoAZTRAzitra Announces Pricing of $1.5 Million Public Offering of Common StockPR NewswireAzitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...